MML Investors Services
ALLO icon

MML Investors Services’s Allogene Therapeutics ALLO Stock Holding History

MML Investors Services’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,000
Closed -$22K – 2805
2025
Q1 		$22K Hold
15,000
– – ﹤0.01% 2675
2024
Q4 		$32K Sell
15,000
-5,000
-25% -$12.3K ﹤0.01% 2641
2024
Q3 		$56K Buy
+20,000
New +$53.3K ﹤0.01% 2536

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MML Investors Services's ALLO Position: Q2 2025 in Review

MML Investors Services sold out of Allogene Therapeutics (ALLO) in Q2 2025, closing a stake of 15,000 shares — an estimated $22K sold.

MML Investors Services first reported a position in ALLO in Q3 2024 and held it in 3 quarters. The position peaked at $56K in Q3 2024. 158 funds tracked by Wall St. Rank hold ALLO as of Q2 2025.

  • MML Investors Services reported no remaining Allogene Therapeutics position as of Q2 2025 after selling out during the quarter.
  • MML Investors Services sold 15,000 Allogene Therapeutics shares in Q2 2025, an estimated $22K.
  • MML Investors Services first reported a position in Allogene Therapeutics in Q3 2024 and held it in 3 quarters.
  • MML Investors Services's Allogene Therapeutics position peaked at $56K in Q3 2024.
  • 158 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2025.

Based on MML Investors Services's 13F filing for Q2 2025, filed 14 Aug 2025.